key: cord-0860780-i03f2fy2 authors: Arias-Murillo, Yazmin R.; Benavides-V., Carlos A.; Salinas-N, María A.; Osorio-Arango, Karime; Plazas-Sierra, Carolina; Cortés, Jorge A. title: SARS-CoV-2/COVID-19 INFECTION IN TRANSPLANT RECIPIENTS AND IN PATIENTS ON THE ORGAN TRANSPLANT WAITING LIST IN COLOMBIA date: 2021-01-13 journal: Transplant Proc DOI: 10.1016/j.transproceed.2020.12.003 sha: 737624ee02e0b2d2d85844f8e564e970b0146c12 doc_id: 860780 cord_uid: i03f2fy2 In an effort to assess our determination to continue transplant activity in Colombia during the Covid-19/pandemic, this study seeks to describe the risk of infection and mortality of transplanted patients versus those on waiting list. Therefore, a descriptive study of SARS-CoV-2/COVID-19 infection in transplant recipients and patients on waiting list was conducted. The data sources were the information systems of the Instituto Nacional de Salud of Colombia: National Donation and Transplant Information System, the National Public Health Surveillance System and the National COVID-19 Data Repository. Characteristics of the patients who tested positive were analyzed and the mortality rate was determined. An RT-PCR test for SARS-CoV-2/COVID-19 was performed in 7% of the transplant recipients included in this study, and 14.8% of them tested positive. Among patients on the waiting list, 15.2% were tested and 16.7% showed positive results. Overall, 1% (84/8,108) of the transplant recipients and 2.5% (74/2,926) of patients on waiting list were infected with SARS-CoV-2/COVID-19. There were no differences in mortality between these groups (p=0.8748). In conclusion, with the data obtained so far, the hospital availability, and the adoption of safety protocols in the institutions, our findings can support the continuity of the transplant activities in this country. SARS-CoV-2: Severe Acute Respiratory Syndrome Coronavirus type 2 ICU: Intensive care unite The Severe Acute Respiratory Syndrome Coronavirus type 2 (SARS-CoV-2) that causes the COVID-19 was declared as a pandemic by World Health Organization (WHO) on March 11, 2020 1 . In Colombia, the first laboratory-confirmed case was notified on March 6, 2020 and the country reported a total of 295,508 confirmed cases and 10,105 deaths (case fatality rate of 3.4%; cumulative mortality rate of 16.4 per 10 5 inhabitants) by July 31, 2020 23 . Information about the risk of COVID-19 among transplant recipients versus patients on the waiting list is controversial, with many countries holding their transplant activity to only urgent cases. The Donation and Transplant Network in Colombia is coordinated by the INS, which is a centralized repository of all the information about the Network's processes. It manages the donation, transplant, and waiting list records for the entire country under the current regulations 4, 5 . Based on hospital availability and the adoption of protection measures for the patient and medical personnel, it was determined to continue with the transplantation activity in our country. The present study seeks to evaluate the initial experience of this measure in terms of infection and mortality. The variables that were analyzed included age, gender, district of residence, socioeconomic status, health social security system regimen, blood group, medical history and pre-existing conditions, type of organ transplanted or to be transplanted, main diagnosis, date of onset of symptoms, consultation and diagnosis, test result for SARS-CoV-2/COVID-19, management center, severity of the disease, vital status, and the date of death. The severity of the disease was defined as mild for patients who were treated at home, moderate for patients who required hospitalization, and severe for those who were admitted to an intensive care unit. For the statistical analysis, the quantitative variables were described through measures of central tendency and dispersion, and the qualitative variables through absolute and relative frequencies. The first analysis examined the characteristics of patients who tested positive for SARS-CoV-2/COVID-19. A subgroup analysis was later performed considering transplant recipients and patients on the waiting list. Finally, the cases of death due to SARS-CoV-2/COVID-19 infection were analyzed. For these cases, the mean number of days from the onset J o u r n a l P r e -p r o o f 3 of symptoms to diagnosis and to the date of death was calculated. Since a multivariate analysis was precluded by the lack of a complete medical record, a relationship between basic information provided by the database and mortality was searched for with a relative risk (RR), an attributable risk (AR), and an attributable risk percent (AR%). The difference in the number of positive cases between the transplant recipients and patients on the waiting list was analyzed by the chi-square test and the difference in mortality between the two groups was analyzed using the Fisher's exact test, considering a p-value of less than 0.05 as significant. The analyses were performed using the IBM SPSS Statistics 22 and Epidat software. This retrospective study used information from secondary sources, without intervention or modification of the biological, physiological, psychological, or social variables of the participating individuals. Therefore, the study was classified as a "risk-free" investigation as established in Resolution 8430 in 1993, by the Ministry of Health. The data from the INS RedDataINS©, SIVIGILA and SISMUESTRAS information systems were analyzed maintaining their validity. The confidentiality of the information was protected according to the established guidelines and current regulations applicable to the National Donation and Transplant Network 4,5 . As on the cut-off date for enrolment in the study (July 31, 2020), 11,034 patients were registered Of the 158 patients who tested positive for SARS-CoV-2/COVID-19, 13.3% (n=21) died of causes related to this disease. Of these, 57.1% (n=12) were transplant recipients, which represents a mortality of 14.3% (12/84) for this group. 42.9% (n=9) of the deceased were on the waiting list, which corresponds to a mortality of 12.2% (9/74) in this group. There were no differences in the rate of mortality between transplant recipients and patients on the waiting list (p=0.8980). had diabetes and dyslipidemia. The RR estimated between the mortality among those with transplantation and those on the waiting list and hypertension was 3.4 (95% CI: 3.13 -3.77) and higher than dyslipidemia (RR: 2.18, 95% CI: 2.05 -2.29) or diabetes (RR: 1.4, 95% CI 1.3 -1.47). The AR estimated for hypertension was 10.5% higher than those for patients with other comorbidities, and the AR% estimates that 71% of the mortality among this group is attributable to hypertension and 29% to other causes. There were no differences in the variables analyzed between on both groups (Error! Reference source not found.). The longest period since transplant was 9 years and 8 months, and the shortest period was 7 months. 11 deceased transplant recipients had a history of high blood pressure, 2 had diabetes and high blood pressure, and 3 had dyslipidemia and high blood pressure. Additionally, 1 patient had a history of smoking, 5 had A-positive blood group and 5 were O-positive. The kidney transplant recipients who died from COVID-19 required hospitalization on an average at 2 days after the onset of symptoms, with a minimum of one day and a maximum of 5 days. They died on an average of 12 days after the onset of symptoms, with a minimum of 1 day and a maximum of 33 days. In general, immunosuppressed patients are at a higher risk of infection, especially during the first year after transplant. The most common viral infections during this period are those caused by cytomegalovirus and polyomavirus BK 7 . Therefore, in the context of a pandemic, the first step was to define whether inducing an immunosuppressed state could increase the risk of infection by COVID-19, while at the same time assessing the impact of this infection in terms of mortality. The best information available at that time was the Spanish waiting list and transplant registry. In a series of 1,314 patients, it was reported that the infection rate was lower in transplant recipients who could be confined to their homes during quarantine, compared to patients who had to continue to travel to dialysis units (hemodialysis in centers, 63% versus transplant recipients, 33%). Moreover, the mortality of patients infected with SARS-CoV-2 was lower among transplant recipients (21.6%) compared to that in the dialysis patients (27.1%) 8 . 9 more severe course of the disease; however, the possible protective effects of immunosuppressive therapy and a milder presentation of the COVID-19 disease are being discussed without much clarity 10, 11 . To date, there are no known reports of SARS-CoV-2 transmission between organ donors and recipients 10,12,13 . Since the transplant procedures are non-elective as they depend on the availability of a donor, organizations dealing with organ donation and transplant explored mechanisms to continue with their activities. In Colombia, from the declaration of the pandemic until July 31, 2020, there were on an average 2,920 patients on the waiting list for a solid organ transplant; hence, continuing with the transplant services was a challenge for the entire healthcare system. Therefore, the next step was to define a safe method to perform the organ extraction and transplant procedures. The The mortality in our study population was three times higher than that of the general population in Colombia (3.4% versus 13.3%), probably due to the higher number of comorbidities in these patients. However, this mortality was lower than that reported in previous studies among the transplant recipients in other countries, which might be related to the measures adopted in the At the cut-off date used in this study, 31% of the infected patients, including transplant/waiting list, were confirmed as recovered. In other studies among this population, the percentage of recovery was highly variable, ranging from 33% to 80%, since it is dependent on the stage of the pandemic in each country at the time of the report 11 . Globally, several countries have reported a decrease in transplant procedures due to the pandemic. According to the INS, as of July 2020, there was a 44.3% decrease in organ transplants from brain dead donors in Colombia, especially between March and May, when a strict quarantine was implemented due to the health emergency, in addition to other measures. This impacted the detection of potential donors, especially from cases of traumatic injury, and there was a high prevalence of positive cases in intensive care units 16 . In the case of living donors, unlike in European countries that restricted the procedures involving live donors due to the congestion of their units, many groups in Colombia continued this activity J o u r n a l P r e -p r o o f 11 since it had variables that were easier to control for both, the donor and the recipient. There was a decrease of 13% in this activity in the country 16 . The results as of July 31, 2020 in Colombia were in conformance with the results from Europe, with a statistically lower incidence of infection of 1.03% (84/8,108) in transplant recipients compared to 2.52% (74/2,926) in patients on the waiting list, who were mostly (94.6%) dialysis patients who probably could not comply with a strict quarantine due to this condition. Due to the higher risk of infection in the transplant population, this group of patients has probably adopted stricter self-isolation and care measures compared to those by the general population, which might also be related to the ongoing education of transplant patients and their families for prevention of infections. Studies in the other countries have shown that kidney transplant patients have modified their behavior, and more than 95% were in isolation at home, thus reducing the risk of infection 17 . The percentage of tests performed in this study was higher in patients on the waiting list than in the transplant recipients, possibly because of the higher risk to which they were exposed due to their dialysis visits. Until the completion of this study, the dialysis units did not have a protocol for periodic assessment of their patients and the indication for testing was based on symptoms or close contacts. However, this higher testing in patients on the waiting list could play a role on the higher infection rate among this group. The incidence of SARS-CoV-2 infection among transplant recipients in Colombia is lower than expected. The study's cut-off date possibly corresponds to the peak of the epidemic in Colombia and 5% of the population was expected to be infected at this time. This percentage is slightly lower than that reported by an international multicentric study, which reported the rate of infection to be 1.5% among kidney transplant recipients. Serological studies in Spain have shown a mean prevalence of 5% and in some areas with high infection rates, such as Madrid, it reached above 10% 18 , which supports the findings of our study that the incidence is lower than in the general population. Case series studies involving kidney transplant recipients have shown a high mortality in some centers (18-28%) [19] [20] [21] . One case series reported rapid progression, associated with a high frequency of immunological changes that could predispose to a faster progression and possibly higher mortality. In our study as well, transplant patients manifested the disease early, had longer duration of hospitalization than the general population, and died in a short span of time, while those on the waiting list manifested the disease later and stayed longer in the hospital, which suggests that there is a deleterious impact of immunosuppression on the progression of the disease. In addition to the risk factors due to the usual comorbidities in these patients 22 , immunosuppression could be an additional risk factor for mortality. However, despite a slight increase in the percentage of transplant recipients who required intensive care management, this difference, as well as mortality, were not statistically different, compared with infected J o u r n a l P r e -p r o o f 13 patients on the waiting list 14.3% versus 12.2%), which might be related to the potential effect of these drugs in modulating the inflammatory storm triggered by the virus 10, 11 . Unlike the high mortality rate (28%) reported in a group in New York 19 in the immediate postoperative period that forced the suspension of the program, the outcomes in our country during the period analyzed have been different, since none of the patients infected during the early perioperative period has died until the study's cut-off date. The mortality of transplant patients in this study was 14.3%. In an analysis of mortality in the immunosuppressed population, the mortality of the transplanted population is variable, ranging from 5% to 67%. However, compared to other populations with the same condition such as cancer or HIV, transplant recipients might have a higher risk of mortality 11 . We consider that with the data obtained so far, the availability of hospital beds and resources, and the biosafety protocols adopted, we can continue with the transplantation activity in our country. However, it is necessary to further monitor COVID-19 infection in the transplant recipients in Colombia during the coming months, to optimize control measures to prevent infection, as well as to further develop strategies for the education of families, caregivers, as well as reopening of the economic (work) and educational sectors (e.g. schools) in the environments of transplant patients. Among the limitations observed in our study is the lack of information on the clinical presentation of patients, which prevents validation of the presence of other comorbidities that affect the risk of infection, hospitalization, or progression in this group of patients. Moreover, there is lack of information related to the general management of these patients in the follow-up centers that are not registered in the National Donation and Transplant Network. COVID-19: cronología de la actuación de la OMS COVID-19 en Colombia Alvis-Guzmán N. Is Colombia an example of successful containment of the COVID-19 2020 pandemic? A critical analysis of the epidemiological data Congreso de Colombia. Ley 1805 de 2016. Congreso de Colombia Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection Cytomegalovirus in solid organ transplant recipients-Guidelines of the American Society of Transplantation Infectious Diseases Community of Practice Informe 3 (18 marzo -11 abril) Registro COVID-19 ERACODA: The ERA-EDTA COVID-19 Database for KRT Patients COVID-19 in Patients with Solid Organ Transplantation: A Systematic Review COVID-19 in Immunocompromised Hosts: What We Know So Far The COVID-19 outbreak in Italy: Initial implications for organ transplantation programs Covid-19: all non-urgent elective surgery is suspended for at least three months in England Lineamiento Técnico Para La Red de Donación y Trasplantes Relacionado Con El Coronavirus SARSCoV-2, Responsable de Ocasionar La Enfermedad Infecciosa Por Coronavirus (COVID-19) .; 2020 Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Infografia Red Donación y Trasplante enero -julio 2019-2020 Do Lifestyle Changes of Renal Transplant Recipients During the Pandemic Reduce the Risk of Coronavirus Disease Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study Covid-19 and Kidney Transplantation Kidney transplantation in the times of covid-19 -a literature review The authors are grateful to the work teams of the INS information systems: SIVIGILA, RedDataINS©, and SISMUESTRAS for their commitment and availability for interoperability and information exchange. The authors received financial support from the INS for the publication of this study. The authors of this manuscript have no conflicts of interest.